Prostate Cancer Diagnostics

68Ga-RM2 PET-MRI Versus MRI Alone for Biochemically Recurrent Prostate Cancer
Andrei Iagaru, MD, highlights his latest research evaluating the diagnostic efficacy of 68Ga-RM2, a GRPR-targeting radiopharmaceutical, in patients with biochemical recurrence of prostate cancer. The primary outcome of the phase 2/3 study was the proportion of patients with PET-positive findings upon 68Ga-RM2 PET-MRI compared with MRI alone after initial therapy, at a per-patient and per-lesion level. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Advertisement
Latest News